Pegylated (mw 20000) Human Sequence Recombinant Uses, Dosage, Side Effects and more
Pegylated (mw 20000) Human Sequence Recombinant is under investigation in clinical trial NCT02585960 (BAX 855 Pk-guided Dosing).
| Trade Name | Pegylated (mw 20000) Human Sequence Recombinant |
| Generic | PEGylated Recombinant Factor VIII |
| PEGylated Recombinant Factor VIII Other Names | Adynovate, Adynovi, Antihemophilic factor (recombinant), pegylated (20 kda), Antihemophilic factor (recombinant), pegylated (mw 20000), Antihemophilic factor, pegylated (mw 20000) human sequence recombinant, PEGylated Recombinant Factor VIII, Pegylated rfviii |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
